Uterine Leiomyoma Competitive Landscape Research Report 2024: R&D Activities Stall with 12 Molecules in the Pipeline, Phase III Holds Only Three Drugs Whereas Phase II Holds Only Two Drugs

Dublin, Jan. 10, 2025 (GLOBE NEWSWIRE) -- The "Uterine Leiomyoma: Competitive Landscape" report has been added to ResearchAndMarkets.com's offering.This reports provides a data-driven overview of the current and future competitive landscape in Uterine Leiomyoma therapeutics.In 2024, more than 16 million incident cases of UL are anticipated in the 16 countries covered in the analyst's epidemiology forecast.Currently, the treatment of UL is dominated by gonadotropin-releasing hormone (GnRH) agonist drugs. R& ...